WellSky to Deliver In-Home Protocols for Patients With Heart Failure

WellSky’s technology platform and provider networks will coordinate the execution of in-home, heart failure protocols to lower hospital readmissions at The Ohio State University Wexner Medical Center

WellSky, a leading health and community care technology company, today announced they will work with The Ohio State University Wexner Medical Center to implement in-home, heart failure care protocols that are intended to reduce hospital readmissions for patients discharged after admission for heart failure.

Heart failure is a leading cause of hospital readmission in the United States, with an average 30-day readmission rate of nearly 25 percent, generating more than one million hospital stays annually.

The WellSky Care Coordination platform and network of personal care and home health providers coordinates the delivery of care to heart failure patients who are voluntarily enrolled in the program at the time of hospital discharge. The WellSky protocols leverage cutting-edge ReDS™ technology, a system that can view the inside of the lungs of heart failure patients. Using this technology from Sensible Medical, clinicians can quickly and accurately assess lung fluid in heart failure patients, enabling the deployment of customized care interventions that are intended to prevent hospital readmissions.

Dr. Dan Bensimhon, a Medical Director of WellSky and Medical Director of Cone Health’s Advanced Heart Failure Clinic, a national leader in designing heart failure care at-home pathways, has been instrumental in designing these protocols. In applying the protocols in multiple health systems across North Carolina, Dr. Bensimhon has realized a 40 percent decrease in readmission rates. In a meta-analysis comprised of seven published clinical studies, researchers found a 60 percent reduction in heart failure readmission rates on average when using the ReDS technology, as compared to standard post-discharge heart failure care.

This new, transformational program powers collaboration between heart failure cardiologists, telehealth clinicians, nurses, and personal caregivers to optimize the care of these patients in the home. Dr. Brent Lampert and Dr. Raymond Benza will lead the program at Ohio State Wexner Medical Center.

“WellSky is excited to work with Dr. Lampert and Dr. Benza on the implementation of this innovative protocol that enables advanced clinical and operational workflows for complex care delivery,” said Bill Miller, WellSky CEO. “By integrating care coordination technology and scaled, connected provider networks, hospital systems can deliver improved outcomes through coordinated condition-specific protocols.”

SourceWellSky®

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”